Follow
Turki Althunian
Turki Althunian
Saudi Food and Drug Authority
No verified email
Title
Cited by
Cited by
Year
Defining the noninferiority margin and analysing noninferiority: an overview
TA Althunian, A de Boer, RHH Groenwold, OH Klungel
British journal of clinical pharmacology 83 (8), 1636-1642, 2017
1562017
Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review
TA Althunian, A de Boer, OH Klungel, WN Insani, RHH Groenwold
Trials 18, 1-9, 2017
752017
Effectiveness of topical vancomycin in the prevention of spinal surgical site infections: a retrospective cohort study
RT Tafish, AF Alkhaldi, A Bourghli, TA Althunian
Antimicrobial Resistance & Infection Control 10, 1-8, 2021
102021
Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines
OM Albalawi, MI Alomran, GM Alsagri, TA Althunian, TM Alshammari
Saudi Pharmaceutical Journal 30 (2), 180-184, 2022
72022
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: a retrospective noninferiority cohort replication study
TA Althunian, A de Boer, RHH Groenwold, KO Rengerink, PC Souverein, ...
Pharmacoepidemiology and Drug Safety 29 (10), 1263-1272, 2020
62020
The impact of regulatory restrictions on pregabalin use in Saudi Arabia: an interrupted time series analysis
TA Althunian, MI Alomran, GM Alsagri, MM Alrasheed, TM Alshammari
Pharmacoepidemiology and Drug Safety 31 (5), 577-582, 2022
52022
Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate
TA Althunian, A de Boer, RHH Groenwold, OH Klungel
Journal of Clinical Epidemiology 104, 15-23, 2018
42018
Assessment of the regulatory dialogue between pharmaceutical companies and the European Medicines Agency on the choice of noninferiority margins
TA Althunian, A de Boer, AK Mantel-Teeuwisse, RHH Groenwold, ...
Clinical Therapeutics 42 (8), 1588-1594, 2020
32020
The association between drug pricing and drug shortage in Saudi Arabia: a retrospective database analysis
MA Alowairdhi, FH Alhussain, MI Alomran, OA Almadani, ...
Journal of Pharmaceutical Policy and Practice 16 (1), 91, 2023
12023
Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in …
TAI Althunian, A De Boer, RHH Groenwold, KO Rengerink, PC Souverein, ...
Pharmacoepidemiology and Drug Safety 28 (S2), 57-58, 2019
12019
Insights into regulatory and design Aspects of bioequivalence trials in Saudi Arabia: A comprehensive analysis
T Althunian, B Alzenaidy, R Aroba, O Almadani, F Alqahtani, A Binajlan, ...
Authorea Preprints, 2023
2023
A large proportion of a Saudi population with type 2 diabetes mellitus was found to be non-adherent to antidiabetics: a retrospective cohort study
T Althunian, OA Almadani, GM Alsagri, HA Badreldin, TM Alshammari
Authorea Preprints, 2023
2023
Drug shortage in Saudi Arabia was mostly common in drugs that are more expensive outside Saudi Arabia: A retrospective database analysis
T Althunian, MA Alowairdhi, FH Alhussain, MI Alomran, OA Almadani, ...
2023
Recording type 2 diabetes mellitus in a standardised central Saudi database: a retrospective validation study
TA Althunian, MM Alrasheed, FA Alnofal, RT Tafish, MA Mira, RA Alroba, ...
BMJ open 13 (3), e065468, 2023
2023
Real-World Analysis of the Safety and Effectiveness of Apixaban Therapy in Cancer Patients with Venous Thromboembolism in Saudi Arabia
L Alabdelmuhsin, M Alwethairi, O Almadani, TA Althunian, HA Badreldin
Journal of Vascular Diseases 2 (1), 102-111, 2023
2023
The association between drug pricing and drug shortage: A retrospective database analysis
M Alowairdhi, F Alhussain, M Alomran, O Almadani, N Alkhammash, ...
2023
Validating the standardized and ICD-9 code of type 2 diabetes mellitus in a Saudi common data model
TAI Althunian, M Alrasheed, F Alnofal, R Tafish, MA Mira, RA Alroba, ...
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 451-451, 2022
2022
Oral Presentation: Analyzing the US Post-Marketing Safety Surveillance of COVID-19 Vaccines
O Albalawi, M Alomran, G Alsagri, T Althunian, T Alshammari
Drug Safety 44 (12), 1395-1396, 2021
2021
The impact of regulatory restrictions on the use of pregabalin: An interrupted time-series
TA Althunian, M Alomran, G Alsagri, M Alrasheed, TM Alshammari
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 360-360, 2021
2021
Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines (preprint)
O Albalawi, M Alomran, G Alsagri, T Althunian, T Alshammari
2021
The system can't perform the operation now. Try again later.
Articles 1–20